Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Share-based Compensation (2016 - 2025)

Syndax Pharmaceuticals has reported Share-based Compensation over the past 11 years, most recently at $11.3 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $11.3 million for Q4 2025, down 8.48% from a year ago — trailing twelve months through Dec 2025 was $47.5 million (up 10.41% YoY), and the annual figure for FY2025 was $47.5 million, up 10.41%.
  • Share-based Compensation for Q4 2025 was $11.3 million at Syndax Pharmaceuticals, down from $12.1 million in the prior quarter.
  • Over the last five years, Share-based Compensation for SNDX hit a ceiling of $13.8 million in Q2 2025 and a floor of $2.8 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $8.2 million (2023), compared with a mean of $7.5 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 104.8% in 2023 and later dropped 8.48% in 2025.
  • Syndax Pharmaceuticals' Share-based Compensation stood at $3.9 million in 2021, then rose by 7.94% to $4.2 million in 2022, then surged by 96.35% to $8.3 million in 2023, then surged by 47.68% to $12.3 million in 2024, then decreased by 8.48% to $11.3 million in 2025.
  • The last three reported values for Share-based Compensation were $11.3 million (Q4 2025), $12.1 million (Q3 2025), and $13.8 million (Q2 2025) per Business Quant data.